Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Elderly show similar antibody response to 1st dose of Astra, Pfizer COVID-19 shots -UK study

CoronavirusApr 14, 2021 09:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. COVID-19 vaccination at Newmarket Racecourse 2/2

By Kate Kelland

LONDON (Reuters) - The first study to directly compare immune reactions between Pfizer (NYSE:PFE)'s and AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on Wednesday.

The UK study also found that a critical component of the immune system known as T cells showed a more enhanced response in those who got the AstraZeneca/Oxford University vaccine than in those who got the Pfizer/BioNTech one.

The scientists behind the study, which analysed blood samples from 165 people in Britain aged between 80 and 99 who had been given a first COVID-19 vaccine dose, said that finding merited further investigation.

While antibodies can block the coronavirus' ability to enter human cells, T cells can act as broader protection by attacking and killing any cells that have been infected with the virus.

"These vaccines are both equivalent and effective at inducing antibody responses in the great majority of people (in this study), even after one dose," said Paul Moss, a professor of haematology at Britain's Birmingham University who co-led the research.

"Both vaccines are good," he told a briefing on the findings.

The researchers also found that immune responses were "markedly enhanced" by prior infection with SARS-CoV-2. Across the whole cohort of 165, evidence of previous natural infection was seen in 8 donors and associated with 691-fold and 4-fold increase in humoral and cellular immune responses, according to the report.

The study was published online as a Lancet preprint before being peer reviewed. It found that key antibodies were present and at similar levels in 93% of the 76 study participants who got the Pfizer single COVID-19 vaccine dose, and 87% of the 89 participants who got the AstraZeneca shot.

Helen Parry, clinical lecturer at Birmingham University who co-led the study, said the tests also showed that a larger proportion of those who got the AstraZeneca vaccine had a detectable T cell response.

That finding adds to other emerging evidence from COVID-19 studies suggesting that antibodies - which stop the coronavirus from being able to attach to human cells - may not be the only important element of immunity, and that T-cells may also have an important protective role.

"We now need to carry out further research to understand what this difference in T cell responses means," said Parry.

Around half of the UK population have had at least one dose of a COVID-19 vaccine, one of the highest rates of inoculation in the world. The vast majority have received either the Pfizer or the AstraZeneca shot.

SOURCE: https:// Preprints with The Lancet, online April 13, 2021.

Elderly show similar antibody response to 1st dose of Astra, Pfizer COVID-19 shots -UK study
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Juan Solis
Juan Solis Apr 14, 2021 11:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Similar? From the study "31% more antibodies from Astrazeneca than 12% from Pfizer" 3-fold is like "similar"?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email